The following narrative explores the history of CETP inhibition, including earlier iterations, one of which resulted in increased risk of ASCVD, explains how obicetrapib differs from prior CETP inhibitors, provides an overview of the available data on the effects of obicetrapib on atherogenic biomarkers, and discusses the future of obicetrapib including the ongoing clinical trials. This evidence concerns the gene CETP and atherosclerosis.